SEC Form S-8 filed by Zevra Therapeutics Inc.
$ZVRA
Biotechnology: Pharmaceutical Preparations
Health Care
As filed with the Securities and Exchange Commission on March 9, 2026
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Zevra Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
| Delaware | 20-5894398 | |||||||
(State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) | |||||||
101 Federal Street
Boston, MA 02110
(Address of Principal Executive Offices) (Zip Code)
Zevra Therapeutics, Inc.
Amended and Restated 2014 Equity Incentive Plan
(Full Title of the Plan)
Timothy J. Sangiovanni, CPA
Senior Vice President, Finance and Corporate Controller
Zevra Therapeutics, Inc.
1180 Celebration Boulevard, Suite 103
Celebration, FL 34747
(Name and Address of Agent for Service)
(321) 939-3416
(Telephone Number, Including Area Code, of Agent for Service)
Copies to:
Nathan Ajiashvili, Esq.
Latham & Watkins LLP
1271 Avenue of the Americas
New York, NY 10020
(212) 906-1200
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
1
EXPLANATORY NOTE
This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 2,274,191 shares of the Registrant’s Common Stock to be issued pursuant to the Registrant’s Amended and Restated 2014 Equity Incentive Plan (the "A&R 2014 Plan"). A Registration Statement of the Registrant on Form S-8 relating to the A&R 2014 Plan is effective.
INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION
STATEMENTS ON FORM S-8
The contents of the Registration Statements on Form S-8 (File Nos. 333-203703, 333-210369, 333-216858, 333-224062, 333-230041, 333-236794, 333-252743, 333-257429, 333-270340, 333-278444, and 333-285760), including any amendments thereto, as filed with the Securities and Exchange Commission (the “Commission”), are incorporated herein by reference and made a part of this Registration Statement.
2
ITEM 8. EXHIBITS
Exhibit Number | Description of the Exhibit | ||||
| 4.1 | |||||
| 4.4 | |||||
| 5.1* | |||||
| 23.1* | |||||
| 23.3* | |||||
| 24.1 | |||||
| 99.1 | |||||
| 99.2 | |||||
| 99.3 | |||||
| 99.4 | |||||
| 107.1* | |||||
* Filed herewith
3
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, State of Massachusetts, on this 9th day of March, 2026.
| Zevra Therapeutics, Inc. | |||||||||||
| By: | /s/ Timothy J. Sangiovanni | ||||||||||
| Timothy J. Sangiovanni, CPA | |||||||||||
| Senior Vice President, Finance and Corporate Controller | |||||||||||
4
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Neil F. McFarlane and Timothy J. Sangiovanni, CPA and each or any one of them, his lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature | Title | Date | ||||||||||||
/s/ Neil F. McFarlane | ||||||||||||||
| Neil F. McFarlane | President, Chief Executive Officer, and Director (Principal Executive Officer) | March 9, 2026 | ||||||||||||
| /s/ Timothy J. Sangiovanni | ||||||||||||||
| Timothy J. Sangiovanni, CPA | Senior Vice President, Finance and Corporate Controller (Principal Financial and Accounting Officer) | March 9, 2026 | ||||||||||||
| /s/Thomas D. Anderson | ||||||||||||||
| Thomas D. Anderson | Director | March 9, 2026 | ||||||||||||
| /s/ John B. Bode | ||||||||||||||
| John B. Bode | Director | March 9, 2026 | ||||||||||||
/s/ Douglas W. Calder | ||||||||||||||
| Douglas W. Calder | Director | March 9, 2026 | ||||||||||||
/s/ Alicia Secor | ||||||||||||||
| Alicia Secor | Director | March 9, 2026 | ||||||||||||
| /s/ Tamara A. Favorito | ||||||||||||||
| Tamara A. Favorito | Director | March 9, 2026 | ||||||||||||
| /s/ Alvin Shih, M.D. | ||||||||||||||
| Alvin Shih, M.D. | Director | March 9, 2026 | ||||||||||||
| /s/ Corey Watton | ||||||||||||||
| Corey Watton | Director | March 9, 2026 | ||||||||||||
5